Gary Pattee, MD
Neurology · Lincoln, NENPI 1396794749
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Amylyx Pharmaceuticals, Inc. at 44.8% of the total. Reporting peaked in 2023 at $63,555 and has fallen 95.5% since, to $2,861 in 2025. Among neurology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 818 payments — averaging $160.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amylyx Pharmaceuticals, Inc.$59K
- Tanabe Pharma America, Inc.$40K
- Biogen$8K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
- Zambon USA Ltd.$3K
- Mitsubishi Tanabe Pharma Development America, Inc.$2K
- plus $13K from 54 others
Across 202 payments — averaging $11,048 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$1.6M
- Mitsubishi Tanabe Pharma Development America, Inc.$188K
- Adamas Pharmaceuticals, Inc.$111K
- PTC Therapeutics, Inc.$96K
- Orion Corporation$92K
- Novartis$46K
- plus $128K from 9 others
What the payments were for
- Consulting fees$41,41431%
- Speaking & faculty fees$49,97138%
- Travel & lodging$22,88417%
- Food & beverage$17,29313%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RELYVRIO$57,139
- Radicava ORS$26,361
- Radicava$25,919
- EXSERVAN$7,150
- FIRDAPSE$1,750
- TYSABRI$300
- SPINRAZA$249
- Epidiolex$137
- ZEPOSIA$123
- NEXVIAZYME$122
How this compares
$131,650 in reported general payments places this provider in the 95th percentile of 105 neurology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 53 | $735,931 |
| ChenodalChenodiol | 11 | $510,273 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 16 | $206,204 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 35 | $198,936 |
| AustedoDeutetrabenazine | 23 | $145,941 |
| RebifInterferon Beta-1a/Albumin | 12 | $129,065 |
| NuedextaDextromethorphan Hbr/Quinidine | 49 | $80,216 |
| Aimovig AutoinjectorErenumab-Aooe | 37 | $34,067 |
| KeppraLevetiracetam | 16 | $20,947 |
| Dimethyl Fumarate | 22 | $11,478 |
| Riluzole | 50 | $9,670 |
| Tegretol XrCarbamazepine | 15 | $8,881 |
| Carbamazepine ErCarbamazepine | 44 | $8,047 |
| Depakote ErDivalproex Sodium | 13 | $7,513 |
| HorizantGabapentin Enacarbil | 12 | $5,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amylyx Pharmaceuticals, Inc.Relyvrio | $58,975 | $206,20416 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $134 | $145,94123 claims |
| EMD Serono, Inc.Rebif | $260 | $129,06512 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $99 | $80,21649 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $50 | $5,61412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 neurology providers in Nebraska.
Other neurology in Lincoln
- James BobenhouseLincoln$14K
- Ana DelgadoLincoln$11K
- Brian BoesLincoln$8K
- Michael VavraLincoln$7K
- Matthew PurbaughLincoln$7K
- Matthew KnissLincoln$5K
- Daniel Crespo ArtunduagaLincoln$5K
- Vekash RajaLincoln$3K
- Erin DennisLincoln$2K
- Navya JosephLincoln$768
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.